nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—Asthenia—Teniposide—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Etodolac—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Etodolac—Melaena—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Etodolac—Malaise—Bleomycin—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Etodolac—Pruritus—Teniposide—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Etodolac—Arrhythmia—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Etodolac—Leukopenia—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Etodolac—Cystitis—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Etodolac—Alopecia—Carmustine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Etodolac—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Etodolac—Body temperature increased—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Etodolac—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Etodolac—Diarrhoea—Teniposide—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Etodolac—Myalgia—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Etodolac—Alopecia—Vincristine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Etodolac—Coma—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Etodolac—Discomfort—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Etodolac—Chills—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Etodolac—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Etodolac—Urine output increased—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Etodolac—Ecchymosis—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Etodolac—Bladder pain—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Etodolac—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Etodolac—Alopecia—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Etodolac—Confusional state—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Etodolac—Vision blurred—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Etodolac—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Etodolac—Tremor—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Etodolac—Oedema—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Etodolac—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Etodolac—Infection—Bleomycin—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Etodolac—Anaemia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Etodolac—Vomiting—Teniposide—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Etodolac—Sepsis—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Etodolac—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Etodolac—Asthenia—Fludarabine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Etodolac—Rash—Teniposide—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Etodolac—Dermatitis—Teniposide—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Etodolac—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Etodolac—Headache—Teniposide—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Etodolac—Pruritus—Fludarabine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Etodolac—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Etodolac—Leukopenia—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Etodolac—Anorexia—Bleomycin—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Etodolac—Anaemia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Etodolac—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Etodolac—Polyuria—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Etodolac—Photosensitivity—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Etodolac—Hypotension—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Etodolac—Diarrhoea—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Etodolac—Convulsion—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Etodolac—Hypertension—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Etodolac—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Etodolac—Nausea—Teniposide—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Etodolac—Anaemia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Etodolac—Vertigo—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Etodolac—Hepatic failure—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Etodolac—Leukopenia—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Etodolac—Myalgia—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Etodolac—Anxiety—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Etodolac—Paraesthesia—Bleomycin—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Etodolac—Malaise—Mitoxantrone—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Etodolac—Dyspnoea—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Etodolac—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Etodolac—Convulsion—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Etodolac—Hypertension—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Etodolac—Confusional state—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Etodolac—Oedema—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Etodolac—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Etodolac—Decreased appetite—Bleomycin—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Etodolac—Myalgia—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Etodolac—Visual disturbance—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Etodolac—Infection—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Etodolac—Vomiting—Fludarabine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Etodolac—Convulsion—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Etodolac—Rash—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Etodolac—Dermatitis—Fludarabine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Etodolac—Hypertension—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Etodolac—Pain—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Etodolac—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Etodolac—Headache—Fludarabine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Etodolac—Tachycardia—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Etodolac—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Etodolac—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Etodolac—Myalgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Etodolac—Anxiety—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Etodolac—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Etodolac—Discomfort—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Etodolac—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Etodolac—Oedema—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Etodolac—Anorexia—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Etodolac—Infection—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Etodolac—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Etodolac—Confusional state—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Etodolac—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Etodolac—Hypotension—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Etodolac—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Etodolac—Oedema—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Etodolac—Nausea—Fludarabine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Etodolac—Infection—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Etodolac—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Etodolac—Shock—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Etodolac—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Urticaria—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Anorexia—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Body temperature increased—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Insomnia—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Etodolac—Irritability—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Etodolac—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Etodolac—Paraesthesia—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Etodolac—Hypotension—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Etodolac—Dyspnoea—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Etodolac—Somnolence—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Etodolac—Anorexia—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Etodolac—Decreased appetite—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Etodolac—Hypotension—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Etodolac—Insomnia—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Etodolac—Paraesthesia—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Etodolac—Constipation—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Etodolac—Pain—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Etodolac—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Etodolac—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Etodolac—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Etodolac—Decreased appetite—Vincristine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Etodolac—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Etodolac—Somnolence—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Etodolac—Feeling abnormal—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Etodolac—Fatigue—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Etodolac—Asthenia—Bleomycin—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Etodolac—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Etodolac—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Etodolac—Constipation—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Etodolac—Pain—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Etodolac—Asthma—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Etodolac—Pruritus—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Etodolac—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Etodolac—Eosinophilia—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Etodolac—Fatigue—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Etodolac—Pancreatitis—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Etodolac—Pain—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Etodolac—Constipation—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Etodolac—Abdominal pain—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Etodolac—Body temperature increased—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Etodolac—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Etodolac—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Etodolac—Pancytopenia—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Etodolac—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Etodolac—Neutropenia—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Etodolac—Dysuria—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Etodolac—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Etodolac—Abdominal pain—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Etodolac—Body temperature increased—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Etodolac—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Etodolac—Urticaria—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Etodolac—Hypersensitivity—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Etodolac—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Etodolac—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Etodolac—Pneumonia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Etodolac—Vomiting—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Etodolac—Rash—Bleomycin—lymphatic system cancer	0.001	0.001	CcSEcCtD
Etodolac—Dermatitis—Bleomycin—lymphatic system cancer	0.001	0.001	CcSEcCtD
Etodolac—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Etodolac—Asthenia—Carmustine—lymphatic system cancer	0.000996	0.000996	CcSEcCtD
Etodolac—Renal failure—Methotrexate—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Etodolac—Stomatitis—Methotrexate—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Etodolac—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Etodolac—Hypersensitivity—Vincristine—lymphatic system cancer	0.000977	0.000977	CcSEcCtD
Etodolac—Sweating—Methotrexate—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Etodolac—Haematuria—Methotrexate—lymphatic system cancer	0.000962	0.000962	CcSEcCtD
Etodolac—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000951	0.000951	CcSEcCtD
Etodolac—Asthenia—Vincristine—lymphatic system cancer	0.000951	0.000951	CcSEcCtD
Etodolac—Diarrhoea—Carmustine—lymphatic system cancer	0.00095	0.00095	CcSEcCtD
Etodolac—Nausea—Bleomycin—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Etodolac—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Etodolac—Asthenia—Mitoxantrone—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Etodolac—Dizziness—Carmustine—lymphatic system cancer	0.000918	0.000918	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Etodolac—Diarrhoea—Vincristine—lymphatic system cancer	0.000907	0.000907	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Etodolac—Hepatitis—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—lymphatic system cancer	0.000899	0.000899	CcSEcCtD
Etodolac—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Etodolac—Vomiting—Carmustine—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Etodolac—Dizziness—Vincristine—lymphatic system cancer	0.000877	0.000877	CcSEcCtD
Etodolac—Rash—Carmustine—lymphatic system cancer	0.000876	0.000876	CcSEcCtD
Etodolac—Dermatitis—Carmustine—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Etodolac—Headache—Carmustine—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Etodolac—Vomiting—Vincristine—lymphatic system cancer	0.000843	0.000843	CcSEcCtD
Etodolac—Rash—Vincristine—lymphatic system cancer	0.000836	0.000836	CcSEcCtD
Etodolac—Dermatitis—Vincristine—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Etodolac—Headache—Vincristine—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Etodolac—Nausea—Carmustine—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Etodolac—Vomiting—Mitoxantrone—lymphatic system cancer	0.000821	0.000821	CcSEcCtD
Etodolac—Rash—Mitoxantrone—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Etodolac—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Etodolac—Chills—Methotrexate—lymphatic system cancer	0.000812	0.000812	CcSEcCtD
Etodolac—Headache—Mitoxantrone—lymphatic system cancer	0.000809	0.000809	CcSEcCtD
Etodolac—Alopecia—Methotrexate—lymphatic system cancer	0.0008	0.0008	CcSEcCtD
Etodolac—Nausea—Vincristine—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Etodolac—Dysgeusia—Methotrexate—lymphatic system cancer	0.000772	0.000772	CcSEcCtD
Etodolac—Nausea—Mitoxantrone—lymphatic system cancer	0.000767	0.000767	CcSEcCtD
Etodolac—Vision blurred—Methotrexate—lymphatic system cancer	0.000743	0.000743	CcSEcCtD
Etodolac—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Etodolac—Anaemia—Methotrexate—lymphatic system cancer	0.000728	0.000728	CcSEcCtD
Etodolac—Malaise—Methotrexate—lymphatic system cancer	0.000711	0.000711	CcSEcCtD
Etodolac—Vertigo—Methotrexate—lymphatic system cancer	0.000708	0.000708	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Etodolac—Convulsion—Methotrexate—lymphatic system cancer	0.000683	0.000683	CcSEcCtD
Etodolac—Myalgia—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Etodolac—Discomfort—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Etodolac—Confusional state—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Etodolac—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Etodolac—Infection—Methotrexate—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Etodolac—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Etodolac—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Etodolac—Anorexia—Methotrexate—lymphatic system cancer	0.000613	0.000613	CcSEcCtD
Etodolac—Hypotension—Methotrexate—lymphatic system cancer	0.000601	0.000601	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000586	0.000586	CcSEcCtD
Etodolac—Insomnia—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—lymphatic system cancer	0.000578	0.000578	CcSEcCtD
Etodolac—Dyspnoea—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Etodolac—Somnolence—Methotrexate—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Etodolac—Dyspepsia—Methotrexate—lymphatic system cancer	0.000566	0.000566	CcSEcCtD
Etodolac—Decreased appetite—Methotrexate—lymphatic system cancer	0.000559	0.000559	CcSEcCtD
Etodolac—Fatigue—Methotrexate—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Etodolac—Pain—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Etodolac—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000526	0.000526	CcSEcCtD
Etodolac—Urticaria—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—lymphatic system cancer	0.000509	0.000509	CcSEcCtD
Etodolac—Body temperature increased—Methotrexate—lymphatic system cancer	0.000509	0.000509	CcSEcCtD
Etodolac—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000474	0.000474	CcSEcCtD
Etodolac—Asthenia—Methotrexate—lymphatic system cancer	0.000462	0.000462	CcSEcCtD
Etodolac—Pruritus—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Etodolac—Diarrhoea—Methotrexate—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
Etodolac—Dizziness—Methotrexate—lymphatic system cancer	0.000425	0.000425	CcSEcCtD
Etodolac—Vomiting—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
Etodolac—Rash—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—lymphatic system cancer	0.000405	0.000405	CcSEcCtD
Etodolac—Headache—Methotrexate—lymphatic system cancer	0.000403	0.000403	CcSEcCtD
Etodolac—Nausea—Methotrexate—lymphatic system cancer	0.000382	0.000382	CcSEcCtD
